← Back to Analyst Consensus 
MSLE Buy
Satellos Bioscience Inc.
Current Price —
Implied Upside —
Analysts 11
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 0 reiterations from 1 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 8, 2026 | Craig-Hallum | initiate | — → Buy | — | 54% |
| Aug 17, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jul 9, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| May 18, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Apr 28, 2026 | Guggenheim | initiate | — → Buy | — | 52% |
| Apr 6, 2026 | Leerink Partners | initiate | — → Outperform | — | 51% |
| Mar 30, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 11, 2026 | Cantor Fitzgerald | initiate | — → Overweight | — | 50% |
Price Target Trend
Mar 27, 2026 Latest: $24.17 Oct 24, 2026
EPS Estimates
0q $-0.63
Lo: $-0.93 Hi: $-0.44
6 analysts ▲1
+1q $-0.68
Lo: $-1.11 Hi: $-0.49
6 analysts +1y $-2.61
Lo: $-4.82 Hi: $-1.32
7 analysts 0y $-2.49
Lo: $-3.27 Hi: $-2.13
5 analysts Cross-Platform Signals
No cross-platform signals in the last 90 days